433,331 Shares in Pfizer Inc. $PFE Acquired by Pinebridge Investments LLC

Pinebridge Investments LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 433,331 shares of the biopharmaceutical company’s stock, valued at approximately $10,790,000.

Other institutional investors have also added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA acquired a new position in Pfizer during the 3rd quarter worth approximately $16,613,000. Penn Davis Mcfarland Inc. raised its stake in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after buying an additional 57,777 shares during the period. Mackenzie Financial Corp raised its stake in Pfizer by 119.6% during the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock worth $79,157,000 after buying an additional 1,691,773 shares during the period. Pzena Investment Management LLC raised its stake in Pfizer by 0.9% during the 3rd quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock worth $168,565,000 after buying an additional 56,484 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after buying an additional 5,978,927 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Stock Performance

Shares of PFE opened at $26.04 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50 day moving average price of $26.62 and a two-hundred day moving average price of $26.29. The firm has a market capitalization of $148.43 billion, a P/E ratio of 19.88 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.